Standing Order
CRISPR Therapeutics AG

Dashboard

CRISPR Therapeutics AG

CRSPNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$3.8B
Price$39.1052w $36.95 – $76.78
Conviction4/ 5
Revenue (TTM)$25M
Revenue growth YoY-33.1%
P/E (trailing)—
Gross margin-676.5%
Operating margin-2104.9%
Net margin-1812.1%
52w price change+5.8%
Next earnings—

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 19
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Nov 12
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics begins recruiting for Phase 1/2 trial of CTX340 in hypertension (NCT07758634).

  • Nov 6
    Ownership changeSEC

    SEC Form 4 insider beneficial ownership change report filed.

  • Nov 5
    Trial readoutClinicalTrials.gov

    CRISPR Therapeutics completes Phase 1 trial NCT05795595 of CTX131 in relapsed/refractory solid tumors

  • Nov 2
    Financial resultsSEC

    CRISPR Therapeutics AG filed 8-K (items 2.02, 9.01) disclosing financial results.

  • Oct 28
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Oct 28
    Ownership changeSEC

    SEC Form 4 filing reporting change in beneficial ownership by insider at CRISPR Therapeutics.

  • Oct 28
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Oct 28
    Ownership changeSEC

    SEC Form 4 filing reporting change in insider ownership for CRISPR Therapeutics AG.

  • Oct 21
    Ownership changeSEC

    SEC Form 4 filing reporting change in beneficial ownership.

  • Oct 20
    Ownership changeSEC

    Form 4 filing reporting change in insider ownership at CRISPR Therapeutics AG.

  • Oct 20
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.

  • Oct 19
    LeadershipSEC

    8-K reports item 5.02 leadership change (director/officer departure or appointment).

  • Oct 16
    Ownership changeSEC

    SEC Form 4 insider transaction filing for CRISPR Therapeutics AG.

  • Oct 15
    Ownership changeSEC

    Form 4 insider transaction filing for CRISPR Therapeutics AG.

  • Oct 15
    Ownership changeSEC

    SEC Form 4 insider transaction filing by CRISPR Therapeutics AG.

  • Oct 8
    Ownership changeSEC

    Form 4 insider trading report filed 2026-10-08.

  • Sep 24
    Ownership changeSEC

    Form 4 insider ownership change filing

  • Sep 24
    Trial initiationClinicalTrials.gov

    Long-term follow-up study (NCT06208878) of CRISPR CAR T therapies updated to ENROLLING_BY_INVITATION status.

  • Sep 22
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease.

Not financial advice — research and opinion only. Disclosures